Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

FRANKLIN LAKES, N.J., Oct. 5, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ Flow Cytometer with the...

BD Granted FDA 510(k) Clearance for BD FACSLyric™ Flow Cytometer with Newly Integrated BD FACSDuet™ Sample Preparation System

Fluidigm

Hologic

Eli Lilly

Luminex

PerkinElmer

QuidelOrtho Corp

QIAGEN

You know what they say! To the most sensitive tests go the spoils.

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

FRANKLIN LAKES, N.J., Oct. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday, November 5, 2020, at 8:00 a.m. (ET). BD will...

BD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

This comes less than three months after the company received an emergency use authorization for the test from the FDA.

Becton, Dickinson Wins Designation Allowing European Sales of Coronavirus Test

Exact Sciences

Guardant Health Inc

Illumina

Natera

Invitae

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

7 Diagnostic and Genomic Stocks Storming Into October

A new coronavirus test that delivers results in just 15 minutes will be available in Europe next month, New Jersey-based medical-device maker Becton Dickinson announced Wednesday. The company expects to start selling its rapid COVID-19 test in the European Union countries by the end of October now that it’s met the requirements to launch the.

Becton Dickinson’s 15-minute COVID-19 test cleared for use in Europe

A rapid test to detect Covid-19 has been given the greenlight in Europe, according to its maker Becton Dickinson.

15-minute coronavirus test gets the green light for a European rollout

FRANKLIN LAKES, N.J., Sept. 30, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the IVD...

BD Announces CE Mark of Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes

ABM Industries

Accenture Plc

Acme United

Automatic Data Processing

Albemarle

Allstate

Andersons

Air Products and Chemicals

Alexandria Real Estate Equities

Artesian Resources

Atrion

Broadcom

Axis Capital

BancFirst

Franklin Resources

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Bristol-Myers

Broadridge Financial

Cardinal Health

C.H. Robinson Worldwide

Comerica

Canadian National Railway Company

American Tower

A weekly summary of dividend activity for Dividend Champions and Contenders.

Dividend Champion And Contender Highlights: Week Of September 27

FRANKLIN LAKES, N.J., Sept. 21, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on previously announced voluntary recalls of the BD Alaris™ System. Three of the recalls, which BD announced on Aug....

BD Announces FDA Classifications for August 4th Recalls of BD Alaris™ System Hardware for Keypads, Incorrect Module Types and/or Sizes, and Channel Error

Medical-testing firm Becton Dickinson says it’s investigating false-positive coronavirus test results reported at nursing homes around the US.

Medical firm probes false-positive COVID-19 tests in US nursing homes

Becton Dickinson Trying To Leverage COVID-19 Opportunities While Fixing Some Longer-Term Issues

Co-Diagnostics

Even top diagnostic test producers got hit hard in late August.

Why Shares of These 3 Coronavirus-Test Makers Saw Big Moves in August

FRANKLIN LAKES, N.J., Sept. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new research study that demonstrated performance of the BD Veritor™ System for Rapid Detection of SARS-CoV-2.

New Head-to-Head Study Demonstrates Equivalency and Accuracy of COVID-19 Rapid Point-of-Care Tests, Despite Different Test Sensitivity Claims

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock?

Becton Dickinson (BDX) Down 9.8% Since Last Earnings Report: Can It Rebound?

Procter & Gamble

Philip Morris

Roper Technologies

Reckitt Benckiser Group PLC

The Top 5 Buys of the MS Global Franchise Fund

Abbott Labs

With more competition for rapid antigen tests on the way, is Quidel or Becton, Dickinson a better buy?

Competition in the Coronavirus Rapid Test Market: What Does it Mean for Quidel and Becton, Dickinson?

Visa

Just sit back and collect the dividend income.

2 Great Stocks You Can Buy and Hold Forever

FRANKLIN LAKES, N.J., Aug. 20, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on a previously announced voluntary recall of the BD Alaris™ System.

BD Provides Update on Previously Disclosed Recall of BD Alaris System Hardware

Lowe's

Microsoft

Home Depot

S&P Global

Walmart

If you're looking to protect your income, dividend stocks are the way to go. Our deep learning algorithms and Artificial Intelligence ("AI") technology has gone through some data to provide you with the Top Dividend Stocks to invest in with your portfolio.

Top Dividend Stocks For August

Pfizer

Thermo Fisher Scientific

High costs make drug developers unlikely picks for the Oracle of Omaha.

Why Warren Buffett Might Not Be Crazy About Biopharma Stocks

Investors had high hopes for its rapid-response COVID-19 test.

Why Shares of Becton, Dickinson Rose 17.6% in July

Becton, Dickinson and Company (BDX) CEO Tom Polen on Q3 2020 Results - Earnings Call Transcript

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

News for Becton, Dickinson and Co. Stock (BDX)